Paul M. Copeland, MD | Psychiatrist.com

Original Research

Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics

April 16, 2007

David C. Henderson, Enrico Cagliero, Paul M. Copeland, et al

Original Research

Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

May 15, 2006

David C. Henderson, Paul M. Copeland, Christina P. Borba, et al

Original Research

Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study

September 15, 2005

David C. Henderson, Dana D. Nguyen, Paul M. Copeland, et al

Original Research

Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists

February 15, 2005

Donald C. Goff, Corinne Cather, A. Eden Evins, et al